$BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Healthcare
Sector
Biotechnology
Industry
Ryan Cohlhepp
CEO
55
Employees
$21.98
Current Price
$896.78M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 3 | $488,461.92 | 24,200 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 5 | $742,110.67 | 36,700 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 10 | $1,721,291.32 | 78,900 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 27 | $4,305,404.08 | 216,510 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Mazumdar Claire Director | Sale | 1,786 | $18.74 | $33,464.10 | View Details |
| Mar 3, 2026 | Cohlhepp Ryan Director | Sale | 4,500 | $18.16 | $81,733.95 | View Details |
| Mar 3, 2026 | Cohlhepp Ryan Director | Sale | 12,892 | $18.16 | $234,158.69 | View Details |
| Mar 3, 2026 | Hyep Ivan Chief Financial Officer | Sale | 13,555 | $18.22 | $246,909.75 | View Details |
| Mar 4, 2026 | Hyep Ivan Chief Financial Officer | Sale | 2,963 | $18.25 | $54,061.71 | View Details |
| Mar 4, 2026 | Raben David Chief Medical Officer | Sale | 16,300 | $18.52 | $301,920.01 | View Details |
| Mar 3, 2026 | Raben David Chief Medical Officer | Sale | 200 | $18.45 | $3,690.00 | View Details |
34 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ27 of 27 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.67
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$ACET โ Adicet Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$ETNB โ 89bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$ARTV โ Artiva Biotherapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$JANX โ Janux Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.